You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 291 No. 11, March 17, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

ApoA-1 Milano and Regression of Atherosclerosis

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Although Dr Nissen and colleagues1 found a 4.2% mean reduction in atheroma, this number is actually substantially less than what has been observed in animal studies. For instance, my colleagues and I reported that a 90-minute infusion of 1 g of recombinant protein in rabbits resulted in a 30% mean reduction of plaque volume.2

I believe, however, that results of these 2 studies are comparable. Although rabbits' atheromatous lesions develop over a few months and comprise nearly 90% free cholesterol-enriched foam cells, this is not the case for human lesions. Such "removable material" (eg, foam cells and cholesterol-enriched debris) represents only 13% to 26% of the material in human plaques, depending on the age or sex of the examined individuals.3-4 Therefore, the 4.2% reduction in human plaque volume approximates the 30% reduction we observed in rabbits. A similar approach in younger individuals with a larger volume of . . . [Full Text of this Article]

Cesare R. Sirtori, MD, PhD
cesare.sirtori@unimi.it
Department of Clinical Pharmacology
University of Milano
Milan, Italy



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial
, , , , , , , , , , , , , and
JAMA. ;290():2292-2300.
FULL TEXT  

ApoA-1 Milano and Regression of Atherosclerosis
, , , and
JAMA. ;291():1319-1319.
FULL TEXT  

ApoA-1 Milano and Regression of Atherosclerosis--Reply

JAMA. ;291():1320-1320.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.